Impact of molecular targeted therapy on hepatic reserve and novel therapeutic strategies for advanced hepatocellular carcinoma

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K17040
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Chiba University
• Principal Investigator: Kondo Takayuki 千葉大学, 医学部附属病院, 助教 (80845090)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 分子標的薬 / 肝癌 / 肝機能 / 肝予備能

Outline of Final Research Achievements

Clinical data on the incidence and predictors of esophageal variceal hemorrhage, ammonia levels, and the incidence and predictors of hepatic encephalopathy within 2 weeks of treatment were retrospectively examined in patients with treatment of molecular-targeted therapy to determine the effects of molecular-targeted therapy on liver function.
For experimental validation, metabolomic analysis was performed using Huh7 cells, a hepatocyte cell line, to examine the effect of molecularly targeted therapy on albumin production in hepatocytes, using a treatment group with molecularly targeted therapy and a control group. The results showed that leucine and the essential amino acid threonine were also decreased in the treatment group compared to the control group. Glutamine, which is necessary for ammonia metabolism, was also shown to be decreased.

Free Research Field

肝疾患

Academic Significance and Societal Importance of the Research Achievements

本研究にて、分子標的薬が肝予備能に与える影響が臨床学データおよび基礎的検証により示された。今後ますます増えることが予想される肝癌に対する分子標的薬治療の肝機能に与える影響の一端を解明することにより今後の臨床やさらなる基礎的研究に生かされることが来される。